My ePortfolio Register   

Cancer cells force normal cells to mimic viruses to help tumours spread, resist treatment

In a study that could explain why some breast cancers are more aggressive than others, researchers say they now understand how cancer cells force normal cells to act like viruses - allowing tumours to grow, resist treatment, and spread.

The virus mimic is detected in the blood of cancer patients, particularly in cases of an aggressive type known as triple-negative breast cancer. Researchers from the Perelman School of Medicine at the University of Pennsylvania say cracking the code of how this process works opens up the possibility of targeting this mechanism for treatment.

They published their findings today in Cell.

In addition to cancer cells, human tumours also contain normal cells like fibroblasts and various immune cells.

Cancer cells corrupt these cells to help tumours grow and spread, and to survive when attacked.

The fibroblasts cause these tumours to show high levels of interferon-stimulated genes (ISGs), which are genes that normally fight off viruses.

The fact that ISGs show up in tumours suggests something inside the tumours is mimicking a virus.

"The conundrum was that in most cases, there was no viral infection in these tumours," said the study's senior author Andy J. Minn, MD, PhD, an associate professor of Radiation Oncology at Penn. "We've been studying this problem for many years, and it's a puzzle we were motivated to solve because cancers with this kind of anti-viral signalling can be particularly aggressive."

It turns out the cancer cells instruct fibroblasts to secrete exosomes - tiny fluid filled sacs that in this case contain special genetic material that makes them look like viruses.

Barzin Nabet, a graduate student and first author of the study, along with other members of Minn's team from the departments of Medicine and Surgery used breast cancer as a model and found that when cancer cells stimulate fibroblasts, the fibroblasts respond by secreting exosomes that are rich in a specific type of RNA known as RN7SL1.

Unlike most RNA in cells, RN7SL1 has a special end that resembles virus RNA.

Under the direction of the breast cancer cells, the fibroblasts ensure the exosomes keep that viral-like end exposed, tricking the cells that take up the exosomes into responding as if there is a viral infection.

"The ability of cancer cells to specifically instruct the fibroblasts to expose the viral-like end of RN7SL1 is a key discovery," Minn said. "If the end remains covered, breast cancer cells wouldn't treat these exosomes like a virus, making them less likely to progress and more likely to respond to treatment. On the other hand, if the end is always exposed, cells would react as if they are infected with a virus all the time."

The ability of certain types of breast cancers to instruct fibroblasts in this way could explain why some breast cancers are more aggressive and inflammatory than others.

Triple-negative breast cancer and BRCA1 cancer, two types known to be aggressive, are both more likely to active anti-viral responses than other less aggressive forms of breast cancer.

"Since we can test the blood of cancer patients to measure the presence of exposed RN7SL1 in exosomes, we can potentially identify patients whose cancers will be the most aggressive because of this virus mimic," Minn said. "Now that we understand how the exposed RNA is generated, we can look to potential therapeutic targets."

The current study, along with a previous related study from Minn's group, suggests the NOTCH pathway could be one of those potential drug targets.

Drugs that block NOTCH can both turn off signals that instruct fibroblasts as well as interfere with the ability of breast cancer to respond to the virus mimic.

Therapy that includes NOTCH inhibitors was effective at treating mice with triple-negative breast cancer.

Source: Perelman School of Medicine at the University of Pennsylvania

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence